CIC
LYEL icon

Cornercap Investment Counsel’s Lyell Immunopharma LYEL Stock Holding History

Cornercap Investment Counsel’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,388
Closed -$65.9K – 509
2024
Q3 		$65.9K Sell
2,388
-2,426
-50% -$71.3K 0.02% 500
2024
Q2 		$140K Sell
4,814
-42
-0.9% -$2K 0.02% 562
2024
Q1 		$217K Hold
4,856
– – 0.03% 554
2023
Q4 		$188K Hold
4,856
– – 0.03% 538
2023
Q3 		$143K Buy
+4,856
New +$231K 0.03% 520
2023
Q2 		– Sell
-4,509
Closed -$213K – 626
2023
Q1 		$213K Buy
+4,509
New +$241K 0.04% 495

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Cornercap Investment Counsel's LYEL Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 2,388 shares — an estimated $65.9K sold.

Cornercap Investment Counsel first reported a position in LYEL in Q1 2023 and held it in 6 quarters. The position peaked at $217K in Q1 2024. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 2,388 Lyell Immunopharma shares in Q4 2024, an estimated $65.9K.
  • Cornercap Investment Counsel first reported a position in Lyell Immunopharma in Q1 2023 and held it in 6 quarters.
  • Cornercap Investment Counsel's Lyell Immunopharma position peaked at $217K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.